L-rhodinose | 64475-25-8

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 氧烷类
• 英文名称: L-rhodinose
• 英文别名: (4S,5S)-4,5-dihydroxy-hexanal (S)-1->5-cyclohemiacetal；β-L-threo-2,3,6-trideoxy-hexopyranose；(2S,5S,6S)-6-Methyltetrahydro-2H-pyran-2,5-diol；(2S,5S,6S)-6-methyloxane-2,5-diol
• CAS: 64475-25-8
• 化学式: C₆H₁₂O₃
• 分子量: 132.159
• InChiKey: ZCYMCBOUZXAAJG-ZLUOBGJFSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  -0.1
• 重原子数：
  9
• 可旋转键数：
  0
• 环数：
  1.0
• sp3杂化的碳原子比例：
  1.0
• 拓扑面积：
  49.7
• 氢给体数：
  2
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  L-rhodinose 在 吡啶 、 三乙胺 作用下， 以 二氯甲烷 为溶剂， 反应 49.5h， 生成
  参考文献：
  名称：

  Landomycin A 的全合成，一种强效抗肿瘤 Angucycline 抗生素

  摘要：

  兰霉素 A 是最长、最有效的抗肿瘤角环素类抗生素，首次全合成，从 2,5-二羟基苯甲酸、3,5-二甲基苯酚、三乙酰 d-葡萄糖和 d-葡萄糖开始，共分 63 个步骤，总产率为 0.34%。 -木糖，具有 21 步的收敛线性序列。

  DOI：

  10.1021/ja205339p

文献信息

• ANTIBIOTIC FIIRV 104/18 COMPLEX AND THE ISOLATED INDIVIDUAL FACTORS THEREOF
  申请人：Fondazione Istituto Insubrico di Ricerca per la Vita

  公开号：US20190002942A1

  公开（公告）日：2019-01-03

  An antibiotic FIIRV 104/18 complex comprising factors F793, F795, F797, F813 and F683, of formula (I), wherein R represents a glycosidic radical as defined in the specification, the isolated individual factors, a method for their production by cultivation of Dactylosporangium FIIRV sp. 104/18 DSM 32068 under aerobic conditions, and pharmaceutical formulations containing them as active ingredient and their use in the treatment of bacterial infections, caused by bacteria of at least one of the genera Enterococci, Streptococci, Staphylococci and Moraxella , including bacteria of multi resistant strains, in particular Staphylococcus spp., Streptococcus spp, and Enterococcus spp. resistant to methicillin and/or vancomycin.
• [EN] ANTIBIOTIC FIIRV 104/18 COMPLEX AND THE ISOLATED INDIVIDUAL FACTORS THEREOF<br/>[FR] COMPLEXE ANTIBIOTIQUE FIIRV 104/18 ET FACTEURS INDIVIDUELS ISOLÉS DE CE DERNIER
  申请人：FOND ST INSUBRICO DI RICERCA PER LA VITA

  公开号：WO2017093114A1

  公开（公告）日：2017-06-08

  An antibiotic FIIRV 104/18 complex comprising factors F793, F795, F797, F813 and F683, of formula (I), wherein R represents a glycosidic radical as defined in the specification, the isolated individual factors, a method for their production by cultivation of Dactylosporangium FIIRV sp. 104/18 DSM 32068 under aerobic conditions, and pharmaceutical formulations containinig them as active ingredient and their use in the treatment of bacterial infections, caused by bacteria of at least one of the genera Enterococci, Streptococci, Staphylococci and Moraxella, including bacteria of multi resistant strains, in particular Staphylococcus spp., Streptococcus spp, and Enterococcus spp. resistant to methicillin and/or vancomycin.